GlassScriptPhysician profile
Anneliesa Allred
NPI 1972979300
$1,598.20
in general payments reported to CMS, 2019-2025
19 companies · $305 in 2025
The $305 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $209 · 2022: $226 · 2023: $414 · 2024: $444 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,163.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $378.42 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $212.41 | 2024-2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $135.60 | 2023-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $121.10 | 2021-2025 | Trintellix |
| Tris Pharma INC | $109.85 | 2023-2024 | Dyanavel Xr |
| Lundbeck LLC | $92.78 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $88.39 | 2021-2025 | |
| Alkermes, INC. | $65.70 | 2024-2025 | Lybalvi, Aristada |
| Eisai INC. | $64.60 | 2021 | |
| Vanda Pharmaceuticals INC. | $59.30 | 2024-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $49.13 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $42.39 | 2023-2024 | Spravato |
| Biogen, INC. | $40.17 | 2024-2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $32.18 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $28.80 | 2023-2025 | Auvelity |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $26.18 | 2023 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $21.28 | 2025 | Austedo Xr |
| Sunovion Pharmaceuticals INC. | $16.29 | 2022 | |
| Novo Nordisk INC | $13.63 | 2024 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anneliesa Allred listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.